Mark Andrew Wilson Nektar Therapeutics (NKTR) insider trading activity

Mark Andrew Wilson is Chief Legal Officer of NEKTAR THERAPEUTICS. Currently has a direct ownership of 230,414 shares of NKTR, which is worth approximately $285,713. The most recent transaction as insider was on May 17, 2024, when has been sold 6,260 shares (Common Stock) at a price of $1.75 per share, resulting in proceeds of $10,955. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 230K

2.64% 3M change

10.58% 12M change

Total Value Held $285,713

Mark Andrew Wilson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 17 2024	SELL Open market or private sale	$10,955 $1.75 p/Share	6,260 Reduced 2.64%	230,414 Common Stock
Feb 20 2024	SELL Open market or private sale	$5,172 $0.68 p/Share	7,606 Reduced 3.11%	236,674 Common Stock
Nov 17 2023	SELL Open market or private sale	$3,517 $0.49 p/Share	7,179 Reduced 2.86%	243,780 Common Stock
Aug 16 2023	SELL Open market or private sale	$5,632 $0.78 p/Share	7,221 Reduced 2.8%	250,959 Common Stock
May 16 2023	SELL Open market or private sale	$5,430 $0.72 p/Share	7,543 Reduced 2.84%	257,680 Common Stock
Feb 16 2023	SELL Open market or private sale	$24,825 $3.0 p/Share	8,275 Reduced 3.03%	265,223 Common Stock
Nov 16 2022	SELL Open market or private sale	$31,023 $3.57 p/Share	8,690 Reduced 3.09%	272,498 Common Stock

Aug 16 2022	SELL Open market or private sale	$15,180 $4.76 p/Share	3,189 Reduced 1.12%	281,188 Common Stock
Aug 15 2022	BUY Grant, award, or other acquisition	-	165,938 Added 36.85%	284,377 Common Stock
May 16 2022	SELL Open market or private sale	$12,387 $3.95 p/Share	3,136 Reduced 2.59%	117,939 Common Stock
Feb 16 2022	SELL Open market or private sale	$40,088 $10.95 p/Share	3,661 Reduced 2.93%	121,075 Common Stock
Dec 16 2021	BUY Grant, award, or other acquisition	-	37,800 Added 23.26%	124,736 Common Stock
Nov 16 2021	SELL Open market or private sale	$86,382 $13.16 p/Share	6,564 Reduced 7.06%	86,436 Common Stock
Nov 15 2021	BUY Grant, award, or other acquisition	-	20,100 Added 17.77%	93,000 Common Stock
Aug 16 2021	SELL Open market or private sale	$26,415 $13.83 p/Share	1,910 Reduced 2.55%	72,900 Common Stock
May 17 2021	SELL Open market or private sale	$35,081 $18.3 p/Share	1,917 Reduced 2.5%	74,810 Common Stock
Feb 16 2021	SELL Open market or private sale	$48,610 $22.37 p/Share	2,173 Reduced 2.75%	76,727 Common Stock
Feb 03 2021	SELL Open market or private sale	$103,941 $19.45 p/Share	5,344 Reduced 6.34%	78,900 Common Stock
Feb 03 2021	SELL Exercise of conversion of derivative security	$47,027 $8.8 p/Share	5,344 Reduced 5.97%	84,244 Common Stock
Dec 18 2020	BUY Grant, award, or other acquisition	-	28,550 Added 26.57%	78,900 Common Stock
Nov 16 2020	SELL Open market or private sale	$26,055 $16.93 p/Share	1,539 Reduced 2.99%	49,850 Common Stock

MAW

Mark Andrew Wilson

Chief Legal Officer

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NKTR shares.

Notify only if

Value

Insider Trading

Get notified when an Nektar Therapeutics insider buys or sells NKTR shares.

Notify only if

Operation

Value

Type

News

Receive news related to NEKTAR THERAPEUTICS

Track Activities on NKTR

Account